NASDAQ:CVAC CureVac (CVAC) Stock Price, News & Analysis $4.66 0.00 (0.00%) As of 09/17/2026 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsNews and TrendsOwnershipSEC Filings About CureVac Stock (NASDAQ:CVAC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CureVac alerts:Sign Up Key Stats Today's Range$4.66▼$4.6650-Day Range$4.66▼$4.6652-Week Range$3.13▼$5.72VolumeN/AAverage Volume992,546 shsMarket Capitalization$1.05 billionP/E Ratio6.47Dividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview CureVac N.V. is a biopharmaceutical company focused on developing medicines and vaccines based on messenger RNA (mRNA) technology. The company’s research programs have addressed infectious diseases, oncology, and other conditions in which mRNA may be used to instruct cells to produce therapeutic proteins or stimulate an immune response. Founded in 2000 and headquartered in Tübingen, Germany, CureVac has developed proprietary mRNA design, manufacturing, and delivery technologies. Its pipeline has included vaccine candidates for infectious diseases, including COVID-19 and seasonal influenza, as well as cancer immunotherapies and protein-replacement treatments. The company has historically pursued development and commercialization through collaborations with pharmaceutical and biotechnology partners, including GSK. CureVac has conducted research and clinical development activities in Europe and the United States. Alexander Zehnder has served as the company’s chief executive officer. CureVac’s programs remain subject to clinical, regulatory, and commercial development, and the company has not established a broad portfolio of marketed products.AI Generated. May Contain Errors. Read More Receive CVAC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CureVac and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CVAC Stock News HeadlinesCureVac sues Moderna for patent infringement over COVID-19 vaccinesApril 24, 2026 | reuters.comCureVac (NasdaqGM:CVAC) Valuation After New mRNA Pipeline Progress And Refined Capital Allocation PlanJanuary 22, 2026 | finance.yahoo.comALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions. | Weiss Ratings (Ad)BioNTech Completes CureVac Takeover and Updates Articles of AssociationJanuary 6, 2026 | tipranks.comBioNTech SE (BNTX) Closes the Acquisition of CureVac N.V.December 23, 2025 | insidermonkey.comBioNTech Completes CureVac Acquisition to Bolster mRNA LeadershipDecember 18, 2025 | tipranks.comCureVac NV (CVAC): A bull case theoryDecember 4, 2025 | msn.comBioNTech Achieves Minimum Condition in CureVac Exchange OfferDecember 3, 2025 | globenewswire.comSee More Headlines CVAC Stock Analysis - Frequently Asked Questions How have CVAC shares performed this year? CureVac's stock was trading at $4.52 at the start of the year. Since then, CVAC stock has increased by 3.1% and is now trading at $4.66. How were CureVac's earnings last quarter? CureVac N.V. (NASDAQ:CVAC) announced its quarterly earnings results on Monday, November, 24th. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.07. The firm had revenue of $63.53 million for the quarter, compared to analyst estimates of $21.40 million. CureVac had a net margin of 199.92% and a negative trailing twelve-month return on equity of 23.03%. When did CureVac IPO? CureVac (CVAC) raised $200 million in an initial public offering on Friday, August 14th 2020. The company issued 13,333,333 shares at $14.00-$16.00 per share. BofA Securities, Jefferies and Credit Suisse served as the underwriters for the IPO and Berenberg and Kempen were co-managers. How do I buy shares of CureVac? Shares of CVAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CureVac own? Based on aggregate information from My MarketBeat watchlists, some other companies that CureVac investors own include NVIDIA (NVDA), PayPal (PYPL), Tesla (TSLA), NIO (NIO), Advanced Micro Devices (AMD), Meta Platforms (META) and Moderna (MRNA). Company Calendar Last Earnings11/24/2025Today9/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (15m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 CVAC's financial health is in the Green zone, according to TradeSmith. CVAC has been in this zone for over 15 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CVAC CIK1809122 Webwww.curevac.com Phone49-70-71988-30Fax49-7071-9883Employees880Year Founded2000Profitability EPS (Trailing Twelve Months)$0.72 Trailing P/E Ratio6.47 Forward P/E Ratio6.47 P/E GrowthN/ANet Income$175.50 million Net Margins199.92% Pretax Margin232.79% Return on Equity-23.03% Return on Assets-19.09% Debt Debt-to-Equity Ratio0.03 Current Ratio3.70 Quick Ratio3.69 Sales & Book Value Annual Sales$70.74 million Price / Sales14.78 Cash Flow$0.99 per share Price / Cash Flow4.73 Book Value$3.36 per share Price / Book1.39Miscellaneous Outstanding Shares224,338,000Free Float219,515,000Market Cap$1.05 billion OptionableNo Data Beta1.77 Social Links 10 Best Stocks to Own - Fall 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:CVAC) was last updated on 9/19/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CureVac N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share CureVac With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
